Quoin pharmaceuticals announces plans to initiate a second clinical trial in netherton syndrome patients

A multicenter open label study of qrx003 topical lotion in netherton syndrome patients who are currently receiving systemic biologic therapy. a multicenter open label study of qrx003 topical lotion in netherton syndrome patients who are currently receiving systemic biologic therapy.
QNRX Ratings Summary
QNRX Quant Ranking